

REPORTED August 23, 2026

CUSTOMER

NAME Luxara Research Company - LuxaraLabs.com

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID: TIR-036_D Received: 08/18/2026
Compound: Tirzepatide Analyzed: 08/23/2026
Report No.: COA-2026-SC-01416 CAS: 2023788-19-2
Lot Number: T10977 Formula: $C_{225}H_{348}N_{48}O_{68}$
Total Mass: 63.8 mg Mol Weight: 4814.6 g/mol
Appearance: Lyophilized powder

SAMPLE PHOTOGRAPH



§ 02 Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	Tirzepatide	Tirzepatide	
Net Peptide Content:	10.00 mg	11.32 mg	
Peptide Label Accuracy:	≥ 90 %	113.2 %	PASS
Chromatographic Purity:	≥ 98 %	99.6 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

SCAN TO VERIFY
COA-2026-SC-01416



VERIFICATION CODE
GWFxRoxo2eyM5Cpr04MK-Q
sidechainanalytics.com/verify

§ 03 LC-MS/MS Detail


METHOD B · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+

PRECURSOR [M+5H]⁵⁺

963.90 Da

Quantifier transition ● MRM

963.90 > 136.10 CE 28 V



ROLE	TRANSITION	CE
● Quantifier	963.9 > 136.1	28 V
■ Qualifier	963.9 > 110.1	33 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.